List of bibliographic references
Number of relevant bibliographic references: 6.
| Ident. | Authors (with country if any) | Title |
|---|
| 000A98 (2014) |
John F. Seymour [Australie] ; Michael Pfreundschuh [Allemagne] ; Marek Trn N [République tchèque] ; Laurie H. Sehn [Canada] ; John Catalano [Australie] ; Eva Csinady [Suisse] ; Nicola Moore [Suisse] ; Bertrand Coiffier [France] | R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes |
| 000B10 (2014) |
Martin Weisser [Allemagne] ; Ru-Fang Yeh [États-Unis] ; Guillemette Duchateau-Nguyen [Suisse] ; Giuseppe Palermo [Suisse] ; Tri Quang Nguyen [Suisse] ; Xiaoyan Shi [États-Unis] ; Susanna Y. Stinson [États-Unis] ; Nancy Yu [États-Unis] ; Annika Dufour [Allemagne] ; Tadeusz Robak [Pologne] ; Galina N. Salogub [Russie] ; Anna Dmoszynska [Pologne] ; Philippe Solal-Celigny [France] ; Krzysztof Warzocha [Pologne] ; Javier Loscertales [Espagne] ; John Catalano [Australie] ; Loree Larratt [Canada] ; Viktor A. Rossiev [Russie] ; Isabelle Bence-Bruckler [Canada] ; Christian H. Geisler [Danemark] ; Marco Montillo [Italie] ; Kirsten Fischer [Allemagne] ; Anna-Maria Fink [Allemagne] ; Michael Hallek [Allemagne] ; Johannes Bloehdorn [Allemagne] ; Raymonde Busch [Allemagne] ; Axel Benner [Allemagne] ; Hartmut Döhner [Allemagne] ; Nancy Valente ; Michael K. Wenger [Suisse] ; Stephan Stilgenbauer [Allemagne] ; David Dornan [États-Unis] | PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. |
| 000C98 (2014) |
Lotfi Benboubker [France] ; Meletios A. Dimopoulos [Grèce] ; Angela Dispenzieri [États-Unis] ; John Catalano [Australie] ; Andrew R. Belch [Canada] ; Michele Cavo [Italie] ; Antonello Pinto [Italie] ; Katja Weisel [Allemagne] ; Heinz Ludwig [Australie] ; Nizar Bahlis [Canada] ; Anne Banos [France] ; Mourad Tiab [France] ; Michel Delforge [Belgique] ; Jamie Cavenagh [Royaume-Uni] ; Catarina Geraldes [Portugal] ; Je-Jung Lee [Corée du Sud] ; Christine Chen [Canada] ; Albert Oriol [Espagne] ; Javier De La Rubia [Espagne] ; LUGUI QIU ; Darrell J. White [Canada] ; Daniel Binder ; Kenneth Anderson ; Jean-Paul Fermand [France] ; Philippe Moreau [France] ; Michel Attal [France] ; Robert Knight ; GUANG CHEN ; Jason Van Oostendorp ; Christian Jacques ; Annette Ervin-Haynes ; Hervé Avet-Loiseau [France] ; Cyrille Hulin [France] ; Thierry Facon [France] | Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma |
| 001527 (2010) |
Tadeusz Robak [Pologne, France, Espagne, Australie, Russie, Canada, Danemark, Italie, Nouvelle-Zélande, Hongrie, Suisse, États-Unis] ; Anna Dmoszynska ; Philippe Solal-Celigny ; Krzysztof Warzocha ; Javier Loscertales ; John Catalano ; Boris V. Afanasiev ; Loree Larratt ; Christian H. Geisler ; Marco Montillo ; Ilya Zyuzgin ; Peter S. Ganly ; Caroline Dartigeas ; András Rosta ; Jörg Maurer ; Myriam Mendila ; M. Wayne Saville ; Nancy Valente ; Michael K. Wenger ; Sergey I. Moiseev | Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia |
| 001994 (2006) |
Mats Brune [Suède, France, Australie, États-Unis, Allemagne, Canada, Israël, Nouvelle-Zélande] ; Sylvie Castaigne ; John Catalano ; Kurt Gehlsen ; Anthony D. Ho ; Wolf-Karsten Hofmann ; Donna E. Hogge ; Bo Nilsson ; Reuven Or ; Ana I. Romero ; Jacob M. Rowe ; Bengt Simonsson ; Ruth Spearing ; Edward A. Stadtmauer ; Jeff Szer ; Elisabeth Wallhult ; Kristoffer Hellstrand | Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia : results of a randomized phase 3 trial |
| 001A78 (2005) |
Robert Marcus [Royaume-Uni, Canada, Espagne, Australie, France, Belgique, Pologne, Portugal] ; Kevin Imrie ; Andrew Belch ; David Cunningham ; Eduardo Flores ; John Catalano ; Philippe Solal-Celigny ; Fritz Offner ; Jan Walewski ; Jo O Raposo ; Andrew Jack ; Paul Smith | CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Antineoplastic agent |
| 4 | Immunotherapy |
| 3 | Human |
| 3 | Rituximab |
| 2 | Antibodies, Monoclonal, Murine-Derived (administration & dosage) |
| 2 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 2 | Cyclophosphamide |
| 2 | Cyclophosphamide (administration & dosage) |
| 2 | Drug combination |
| 2 | Humans |
| 2 | Treatment |
| 1 | Acute myelocytic leukemia |
| 1 | Adolescent |
| 1 | Adult |
| 1 | Advanced stage |
| 1 | Aged |
| 1 | Aged, 80 and over |
| 1 | Angiogenesis Inhibitors (administration & dosage) |
| 1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 1 | Antiinflammatory agent |
| 1 | Bevacizumab |
| 1 | Cancerology |
| 1 | Chemotherapy |
| 1 | Chronic lymphocytic leukemia |
| 1 | Clinical trial |
| 1 | Combined Modality Therapy |
| 1 | Comparative study |
| 1 | Consolidation treatment |
| 1 | Dexamethasone |
| 1 | Disease-Free Survival |
| 1 | Doxorubicin (administration & dosage) |
| 1 | Female |
| 1 | First line treatment |
| 1 | Fludarabine |
| 1 | Focal Adhesion Kinase 1 (genetics) |
| 1 | Follicular lymphoma |
| 1 | Gene Expression |
| 1 | Histamine dihydrochloride |
| 1 | Immunomodulator |
| 1 | Interleukin 2 |
| 1 | Lenalidomide |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (enzymology) |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (genetics) |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (therapy) |
| 1 | Lymphoma, Large B-Cell, Diffuse (diagnosis) |
| 1 | Lymphoma, Large B-Cell, Diffuse (drug therapy) |
| 1 | Male |
| 1 | Medicine |
| 1 | Middle Aged |
| 1 | Monoclonal antibody |
| 1 | Myeloma |
| 1 | Phase III trial |
| 1 | Prednisone |
| 1 | Prednisone (administration & dosage) |
| 1 | Progression free survival |
| 1 | Prolonged |
| 1 | Proportional Hazards Models |
| 1 | RNA, Messenger (genetics) |
| 1 | RNA, Messenger (metabolism) |
| 1 | RNA, Neoplasm (genetics) |
| 1 | RNA, Neoplasm (metabolism) |
| 1 | Randomization |
| 1 | Recurrence |
| 1 | Retrospective Studies |
| 1 | Survival |
| 1 | Therapeutic protocol |
| 1 | Treatment Outcome |
| 1 | Vidarabine (administration & dosage) |
| 1 | Vidarabine (analogs & derivatives) |
| 1 | Vincristine |
| 1 | Vincristine (administration & dosage) |
| 1 | Young Adult |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "John Catalano"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "John Catalano" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= John Catalano
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
